Biohaven closed at $15.24 on Nov 4, down 2.37%, 10.1% below its 52-week closing high. Volume of 1.7M shares was 0.45× its 20-day average (below normal).
Split-adjusted performance: +26.2% over one month, +51.8% over six months, +2.6% over one year.
Short interest was 17.9M shares at the Oct 15 settlement, down 6.1% from the prior report (14.9% of float, 9.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BHVNBiohaven | $15.24 | −2.37% | +51.8% | — | — | — | $2.30B | |
| IMNMImmunome | $19.52 | −3.89% | −16.1% | −100.0% | — | — | $2.30B | Compare |
| VERAVera Therapeutics | $31.97 | +4.10% | −12.6% | — | — | — | $2.30B | Compare |
| AUPHAurinia Pharmaceuticals | $17.11 | +3.32% | +5.3% | +13.9% | 37.9% | 7.3 | $2.29B | Compare |
| PVLAPalvella Therapeutics | $162.28 | +6.11% | +24.7% | — | — | — | $2.34B | Compare |
| SEPNSepterna | $47.88 | +9.57% | +93.8% | +22375.6% | −48.7% | — | $2.23B | Compare |
| TRLVTrulieve Cannabis | $11.60 | +0.52% | — | — | −149.8% | — | $2.23B | Compare |
| ZYMEZymeworks | $30.94 | +2.69% | +12.1% | −90.6% | −980.8% | — | $2.22B | Compare |
| PRGOPERRIGO | $15.83 | +0.83% | +29.1% | −3.2% | 7.3% | — | $2.20B | Compare |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
